These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33045457)

  • 1. Principal Cause of Poor Visual Acuity after Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 23.
    Okeagu CU; Agrón E; Vitale S; Domalpally A; Chew EY; Keenan TDL;
    Ophthalmol Retina; 2021 Jan; 5(1):23-31. PubMed ID: 33045457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.
    Keenan TD; Vitale S; Agrón E; Domalpally A; Antoszyk AN; Elman MJ; Clemons TE; Chew EY;
    Ophthalmol Retina; 2020 Jan; 4(1):3-12. PubMed ID: 31395505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration: FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1.
    Gale RP; Airody A; Sivaprasad S; Hanson RLW; Allgar V; McKibbin M; Morland AB; Peto T; Porteous M; Chakravarthy U;
    Ophthalmol Retina; 2024 Jun; 8(6):545-552. PubMed ID: 38171416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
    Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
    JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
    Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision.
    Toth LA; Stevenson M; Chakravarthy U
    Retina; 2015 Oct; 35(10):1957-63. PubMed ID: 25946692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes.
    Spooner K; Fraser-Bell S; Hong T; Phan L; Wong JG; Chang A
    Ophthalmol Retina; 2021 Jun; 5(6):511-518. PubMed ID: 33007523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Subretinally Administered Palucorcel for Geographic Atrophy of Age-Related Macular Degeneration: Phase 2b Study.
    Heier JS; Ho AC; Samuel MA; Chang T; Riemann CD; Kitchens JW; Slakter JS; Leiderman YI; Spencer R; Williams GA; Hickson-Curran SB; Keane M; Baldassarre JS;
    Ophthalmol Retina; 2020 Apr; 4(4):384-393. PubMed ID: 32033908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40.
    Christakis PG; Agrón E; Klein ML; Clemons TE; Campbell JP; Ferris FL; Chew EY; Keenan TD;
    Ophthalmology; 2020 Jun; 127(6):784-792. PubMed ID: 31899035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
    JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
    Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration.
    Nguyen V; Daien V; Guymer R; Young S; Hunyor A; Fraser-Bell S; Hunt A; Gillies MC; Barthelmes D;
    Ophthalmology; 2019 Jan; 126(1):64-74. PubMed ID: 30149035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
    Patel Y; Miller DM; Fung AE; Hill LF; Rosenfeld PJ
    Ophthalmol Retina; 2020 Feb; 4(2):141-147. PubMed ID: 31735634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
    Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Results of Full Macular Translocation for Choroidal Neovascularization in Age-Related Macular Degeneration.
    van Romunde SH; Polito A; Bertazzi L; Guerriero M; Pertile G
    Ophthalmology; 2015 Jul; 122(7):1366-74. PubMed ID: 25881514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: A single-centre French study.
    Wolff B; Macioce V; Vasseur V; Castelnovo L; Michel G; Nguyen V; Daien V; Mauget-Faÿsse M; Gillies M
    Clin Exp Ophthalmol; 2020 Jul; 48(5):636-643. PubMed ID: 32112667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
    JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.